Source-grounded facts extracted from Eton Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Eton Pharmaceuticals, Inc. shareholders approved Ratification of the Appointment of Grant Thornton LLP as the Company's Independent Registered Public Accounting Firm for the year ending December 31, 2026 at the 2026-06-09 meeting.
“Proposal 2: Ratification of the Appointment of Grant Thornton LLP as the Company ’ s Independent Registered Public Accounting Firm for the year ending December 31, 2026 For Against Abstain 16,942,328 3,236,671 5,301”
Eton Pharmaceuticals, Inc. shareholders voted on Election of Directors at the 2026-06-09 meeting.
“Proposal 1: Election of Directors Nominee For Withheld Broker Non-Votes Jenn Adams 13,370,948 2,149,317 4,664,035 Charles J. Casamento 9,925,548 5,594,717 4,664,035”
Eton Pharmaceuticals, Inc. entered into Supply and Distribution Agreement for IMPAVIDO® with affiliate of Knight Therapeutics, Inc. valued at $4.25 million fixed fees plus up to $4.0 million sales milestones and 55%/50% net sales share (effective 2026-05-18).
“On May 18, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) oral capsules with an affiliate of Knight Therapeutics, Inc. (“Supplier”).”
Eton Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $24.3 million, EPS $0.05. Guidance raised.
“Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 ● Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million ● Q1 2026 fully diluted GAAP EPS of $0.05”
Eton Pharmaceuticals, Inc. amended credit facility with SWK Funding LLC at SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0% maturing December 2027.
“On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.”
Eton Pharmaceuticals, Inc. amended SWK Credit Agreement with SWK Funding LLC (effective 2026-04-09).
“On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”).”
Eton Pharmaceuticals, Inc. reported the fourth quarter and twelve months ended December 31, 2025 results: revenue $21.3 million, EPS basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.. Guidance raised.
“--- EX-99.1 2 ex_889836.htm EXHIBIT 99.1 ex_889836.htm Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results ● Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 ● Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and”
Eton Pharmaceuticals, Inc. entered into Licensing Agreement with Pierre Fabre Medicament Sas valued at $14.0 million upfront (effective 2026-02-27).
“On February 27, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a licensing agreement and acquired the U.S. rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas (“Licensor”).”
Eton Pharmaceuticals, Inc. completed an acquisition involving Pierre Fabre Medicament Sas for $14.0 million upfront and an 8% royalty on net sales for the duration of the product’s patent protected life, plus approximately $1.5 million of inventory at cl (closed 2026-02-27).
“rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas (“Licensor”). HEMANGEOL® is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.”
Eton Pharmaceuticals, Inc. completed an acquisition involving Ipsen S.A. (closed 2024-12-19).
“on December 1 9, 2024, the Company completed its purchase (the “Acquisition”) of Increlex® (“Increlex”) from Ipsen S.A. (“Ipsen”).”
Eton Pharmaceuticals, Inc. engaged Grant Thornton LLP as its auditor.
“On June 13, 2025, the Audit Committee approved the appointment of Grant Thornton LLP ("Grant Thornton") as the Company’s new independent registered public accounting firm for the Company's fiscal year ended December 31, 2025.”
Eton Pharmaceuticals, Inc. dismissed Crowe LLP as its auditor.
“On June 13, 2025, the Company dismissed Crowe LLP as the Company’s independent registered public accounting firm, effective June 13, 2025.”
Eton Pharmaceuticals, Inc. completed an acquisition involving Ipsen S.A. (closed 2024-12-19).
“on December 19, 2024, Eton Pharmaceuticals, Inc. (the "Company") completed its purchase (the "Acquisition") of the Increlex product from Ipsen S.A.”
Eton Pharmaceuticals, Inc. completed an acquisition involving Ipsen S.A. (closed 2024-12-19).
“on December 19, 2024, Eton Pharmaceuticals, Inc. (the "Company") completed its purchase (the "Acquisition") of the Increlex product from Ipsen S.A. ("Ipsen").”
Eton Pharmaceuticals, Inc. completed an acquisition involving Teva Pharmaceuticals USA, Inc. for $7.0 million at closing (closed 2024-12-31).
“product to the third party and the third party is responsible for all commercialization activities. Under the terms of the purchase agreement, the Company purchased Galzin® for $7.0 million at closing and paid an additional $0.2 million for product inventory. The Company will also pay Teva a royalty of 10% of U.S. net sales through the tenth anniversary of the”
Eton Pharmaceuticals, Inc. completed an acquisition involving Ipsen S.A. for $22.5 million at closing, plus an additional $8.7 million for product inventory (closed 2024-12-19).
“to 18-years-old who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). Under the terms of the purchase agreement, the Company acquired Increlex® for $22.5 million at closing, plus an additional $8.7 million for product inventory. The Company will also make payments to seller of $2.5 million on each of the first and second anniversaries of”
Eton Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $8.0 million, net income Net loss for the first quarter of 2024 was $0.8 million, EPS $0.03 per basic and diluted share.
“Net revenues for the first quarter of 2024 were $8.0 million compared with $5.3 million in the prior year period, an increase of 50%.”
Eton Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2023 results: revenue $7.3 million, net income $2.3 million, EPS $0.09 per basic and diluted share.
“Net revenue: Net product sales and royalty revenues for the fourth quarter of 2023 increased by 109% to $7.3 million compared to $3.5 million in the prior year period”
Eton Pharmaceuticals, Inc. reported full year 2023 results: revenue approximately $30 million in total revenue this year. Guidance raised.
“Given our strong performance through the first half of the year, we have increased our revenue expectation and now anticipate reaching approximately $30 million in total revenue this year," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.”
Eton Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $12.0 million, net income $4.6 million, EPS $0.18 per basic and diluted share.
“Net Revenue: Net sales for the second quarter of 2023 were $12.0 million compared with $7.4 million in the prior year period. Net sales included $5.5 million of licensing payments received during the quarter related to the sale of Eton’s neurology product royalties and milestones to Azurity Pharmaceuticals, compared to $5.0 million of licensing revenue in the prior year period related to the sale of multiple hospital products to Dr. Reddy’s. Product sales and royalty revenue were $6.5 million for the second quarter of 2023 compared with $2.4 million in the prior year period, an increase of 175% over the prior year period and 22% over the first quarter of 2023. The year-over-year increase in product sales and royalty revenue was primarily driven by growth in ALKINDI SPRINKLE and Carglumic Acid tablets. Gross Profit : Gross profit for the second quarter of 2023 was $9.7 million compared with $4.6 million in the prior year period. The growth was driven by the sale of the Company’s neurolo”
Eton Pharmaceuticals, Inc. terminated Asset Purchase Agreement with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation (collectively, the “Debtors”), Janet M. Nesse, as Bankruptcy Trustee for the bankruptcy estates of the Debtors, and certain other affiliates of the Debtors valued at $800,000 (effective 2023-06-30).
“(the “Company”) terminated its Asset Purchase Agreement with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation (collectively, the “Debtors”), Janet M.”
Eton Pharmaceuticals, Inc. amended a asset purchase with Azurity Pharmaceuticals, Inc. valued at $5.5 million (effective 2023-06-15).
“Also, on June 15, 2023, the Company entered into an amendment to the Asset Purchase Agreement dated December 31, 2020 (the “Original Agreement”) by and between the Company and Azurity Pharmaceuticals, Inc. (“Azurity”). Under the amendment, the Company will sell back to Azurity the royalty interests it received under the Original Agreement for a total consideration of $5.5 million.”
Eton Pharmaceuticals, Inc. entered into Asset Purchase Agreement with Wellstat Therapeutics Corporation, Wellstat Biologics Corporation, Janet M. Nesse, as Bankruptcy Trustee, and certain other affiliates valued at $37 million (effective 2023-06-09).
“On June 9, 2023, Eton Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation (collectively, the “Debtors”), Janet M. Nesse, as Bankruptcy Trustee for the bankruptcy estates of the Debtors, and certain other affiliates of the Debtors, whereby the Company was named the “stalking horse bidder” in the bankruptcy proceedings of the Debtors and agreed to acquire the commercial assets of the Debtors for consideration of $37 million.”
Eton Pharmaceuticals, Inc. shareholders approved Ratification of the Appointment of KMJ Corbin & Company LLP as the Company's Independent Registered Public Accounting Firm for the year ending December 31, 2023 at the 2023-06-13 meeting.
“Proposal 2: Ratification of the Appointment of KMJ Corbin & Company LLP as the Company's Independent Registered Public Accounting Firm for the year ending December 31, 2023 For Against Abstain Broker Non-Votes 18,092,275 63,090 37,600 0”
Eton Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-13 meeting.
“Proposal 1: Election of Directors Nominee For Against Abstain Broker Non-Votes Jenn Adams 11,008,471 393,816 3,567 6,787,111 Charles J. Casamento 10,808,753 594,949 2,152 6,787,111”
Eton Pharmaceuticals, Inc. reported Q1 2023 results: revenue $5.3 million, net income -$2.7 million, EPS -$0.10.
“Net Revenue: Net revenues for the first quarter of 2023 were $5.3 million compared with $2.2 million in the prior year period. In both periods, revenue was comprised entirely of product sales and royalties, and the increase was driven primarily by growth in ALKINDI SPRINKLE and Carglumic Acid. Gross Profit : Gross profit for the first quarter of 2023 was $3.3 million compared with $1.3 million in the prior year period. Research and Development (R&D) Expenses : R&D expenses for the first quarter of 2023 were $0.5 million compared to $1.6 million in the prior year period. The decrease in R&D expenses was due primarily to a $0.5 million one-time development milestone payment made in the first quarter of 2022. General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2023 were $5.3 million compared to $4.8 million in the prior year period. The increase in G&A expenses was due primarily to incremental employee-related expenses associated with our sales force expansion”
Eton Pharmaceuticals, Inc. reported financial results for fourth quarter ended December 31, 2022.
“Net income for the fourth quarter of 2022 was $0.9 million or $0.04 per basic and diluted share compared to a net income of $1.0 million or $0.04 per diluted share in the prior year period”
Eton Pharmaceuticals, Inc. reported fourth quarter and year ended December 31, 2022 results: revenue $8.5 million, net income $0.9 million, EPS $0.04 per basic and diluted share.
“Net revenues for the fourth quarter of 2022 were $8.5 million compared with $6.1 million in the prior year period”
David Krempa was appointed as Chief Business Officer at Eton Pharmaceuticals, Inc..
“Effective March 1, 2023, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) has appointed David Krempa to the position of Chief Business Officer.”
Eton Pharmaceuticals, Inc. reported third quarter ended September 30, 2022 results: revenue $3.2 million, net income Net loss of $3.0 million or $0.12 per basic and diluted share, EPS $0.12 per basic and diluted share.
“and Recent Business Highlights Reported seventh straight quarter of sequential growth in product sales and royalty revenue. Eton reported total third quarter 2022 revenue of $3.2 million, comprised entirely of product sales and royalty revenue, representing growth of 315% over the prior year and 37% over the second quarter of 2022. Continued strong growth in”
Wilson Troutman retired as Chief Financial Officer, Corporate Secretary and Treasurer at Eton Pharmaceuticals, Inc..
“Mr. Gruber succeeds Wilson Troutman, who retired as Chief Financial Officer, Corporate Secretary and Treasurer of the Company effective April 11, 2022 as well.”
James Gruber was appointed as Chief Financial Officer, Corporate Secretary and Treasurer at Eton Pharmaceuticals, Inc..
“Effective April 11, 2022 the Board of Directors (the “Board”) of Eton Pharmaceuticals, Inc. (the “Company”) appointed James Gruber to serve as the Company’s Chief Financial Officer, Corporate Secretary and Treasurer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.